Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of carfilzomib in combination with cyclophosphamide and
etoposide for children with relapsed/refractory solid tumors or leukemia. The medications
cyclophosphamide and etoposide are standard drugs often used together for the treatment of
cancer in children with solid tumors or leukemia.
Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults
with multiple myeloma (a type of cancer). However, this drug is not approved to treat
children with relapsed/refractory solid tumors or leukemia. With this research, we plan to
determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and
etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.